REGENXBIO and UPenn Reach $39 Million Patent Settlement With Sarepta Over Elevidys

REGENXBIO and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent to resolve patent litigation tied to AAVrh74-based gene therapies, including Elevidys. Sarepta will pay REGENXBIO $39.0 million within 10 days of the effective date, and all ongoi…